Royalty Pharma CEO Says He Doesn't 'See Any Negatives' Politically, Day After Midterms
Pablo Legorreta pitched a business built to work under any administration as Royalty Pharma lifted its 2026 receipts outlook to $3.5 billion–$3.55 billion.
Royalty Pharma Chief Executive Pablo Legorreta told analysts on the company's Wednesday earnings call that he does not "see any negatives in what's happened politically," a day after the midterm elections, as the company raised its 2026 portfolio receipts guidance to $3.5 billion–$3.55 billion from $3.4 billion–$3.5 billion.
A business built for any administration
A Bank of America analyst asked Legorreta, who is also chairman, about drug-price policy after the election. The analyst described the consensus as gridlock and congressional hearings, and asked about longer-term risks to existing U.S. government drug-pricing agreements and Democratic champions of Medicare for all.
Legorreta said it is "early days to see how this is going to evolve," and that the company will watch the coming weeks and months closely. He then argued the business "can do well in good markets, bad markets," and in "different political environments, different kinds of administrations," which he credited for three decades of returns and growth.
He added that the U.S. must keep funding basic science, including academic research through the NIH, and said the chances of the U.S. supporting research "have increased."
Royalty Pharma buys royalties on biopharmaceutical products, meaning contractual rights to a share of a drug's sales, and also funds drug development in exchange for royalties.
Third straight guidance raise
CFO Terry Coyne said portfolio receipts, the company's top line, grew 9% in the third quarter to $890 million. Royalty receipts, its recurring cash inflows, rose 9% in the quarter and 12% for the first nine months.
The new outlook assumes royalty receipts growth of around 10% to 11%, against 7% to 10% before. It follows the company's standard practice of excluding any future royalty acquisitions, Coyne said, and it is the third consecutive quarterly increase.
The company has returned about 28% of its portfolio cash flow to shareholders this year, Coyne said, roughly $590 million through dividends and share repurchases of over $180 million. Cash stood at $514 million at the end of September, with $8.8 billion of investment-grade debt and an undrawn $1.8 billion revolver.
The pelacarsen charge
A Goldman Sachs analyst noted that the failed Novartis pelacarsen trial brought a $150 million non-cash impairment charge. Legorreta said the company structured the investment protectively, so it will "still make our money back plus a small return."
Executive Vice President Marshall Urist said the royalty interest in Spinraza will revert to Ionis after Royalty Pharma receives $550 million, a 1.1 times return on the $500 million funded. Detailed pelacarsen data is due at the American Heart Association meeting this weekend.
Urist also pointed to an FDA decision on GSK's Nela Delkip and phase three lupus results for Biogen's litifilimab, both expected later this year.
Royalty Pharma has deployed $1.6 billion of capital so far this year, Coyne said, and expects pelacarsen's detailed data this weekend.
Sources
- Royalty Pharma: Q3 Earnings Snapshot | 9news.com — Associated Press
- Royalty Pharma : Articles :: Law360 — law360.com
- Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth Today — benzinga.com
- Royalty Pharma reports third quarter 2026 results — globenewswire.com